An Act to renumber 253.105 (3); to amend 253.105 (1) (b), 253.105 (2) (intro.) and 292.01 (5); to create 253.105 (1) (bg), 253.105 (1) (br), 253.105 (2) (c) and (d), 253.105 (2r), 253.105 (3) (b) and 281.17 (11) of the statutes; Relating to: prescription, use, and disposal of abortion-inducing drugs and providing a penalty.
Impact
This bill amends existing statutes related to abortion-inducing drugs, reinforcing physician accountability and expanding their legal obligations. It specifies that manufacturers of these drugs must also properly manage their disposal and mitigate any harmful environmental impact caused by improper disposal, specifically regarding endocrine disruptors. This aligns with broader environmental regulations, making manufacturers potentially liable for hazardous substance discharges into the environment, thus incorporating additional layers of responsibility and oversight in the medical and pharmaceutical sectors.
Summary
Assembly Bill 718 focuses on the prescription, use, and proper disposal of abortion-inducing drugs. The proposed legislation introduces several new requirements for physicians who prescribe these medications, including mandatory follow-up appointments within seven days to evaluate the patient's health and the provision of specific disposal kits for medical waste. By establishing these requirements, AB718 seeks to enhance patient safety and ensure that women receiving these drugs are monitored for health complications immediately after their use.
Contention
The bill may be subject to debate and contention, particularly from different stakeholder groups. Proponents of AB718 likely argue this legislation is crucial for safeguarding patients' health and the environment, while opponents may view it as excessive regulation. Concerns might be raised about the burden on physicians and clinics to comply with heightened requirements and the implications for access to abortion-related healthcare. As this bill introduces penalties and liabilities both for medical providers and drug manufacturers, it highlights the ongoing discussions in the legislative field regarding women's reproductive rights and public health responsibilities.
A bill for an act relating to abortions including informed consent, dispensing abortion-inducing drugs, and reporting abortion-inducing drug complications.(See HF 2563, HF 2788.)
Relating to the provision of abortion-inducing drugs, including the enforcement of and exceptions to laws regulating the provision of abortion-inducing drugs; providing a civil penalty.
A bill for an act relating to abortions including informed consent, dispensing abortion-inducing drugs, and reporting abortion-inducing drug complications.
A bill for an act relating to abortions including informed consent, dispensing abortion-inducing drugs, and reporting abortion-inducing drug complications.(Formerly HSB 704; See HF 2788.)
An Act to amend and reenact ยง 32.1-276.7:1 of the Code of Virginia and to amend the Code of Virginia by adding in Title 32.1 a chapter numbered 7.3, consisting of sections numbered 32.1-276.12, 32.1-276.13, and 32.1-276.14, and by adding in Article 1 of Chapter 34 of Title 54.1 a section numbered 54.1-3431.1, relating to prescription drug affordability advisory panel established; maximum fair price; annual reports; civil penalties.